Evaluation of STK17B as a cancer immunotherapy target utilizing highly potent and selective small molecule inhibitors by Felix Scheuplein, Florian Renner, John E. Campbell, Robert Campbell, Chris De Savi, Jan Eckmann, Holger Fischer, Jie Ge, Luke Green, Peter Jakob, Joseph L. Kim, Caitlin Kinkema, Katie McGinn, Ricardo Medina, Annemarie Müller, Nisha Perez, Emanuele Perola, Yoav Timsit, Tary Traore, Ulrike Hopfer, Stefka Tyanova, Manuel Tzouros, Ruduan Wang, Richard Woessner, Marion Dorsch, James R. Bischoff

Subjects: Get full text